NASDAQ | Warrant
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management.
It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform.
It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations.
Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 10.03 K Increased by +N/A% | -1.93 M Decreased by -67.91% | Decreased by -19.27 K% Decreased by N/A% |
| Jun 30, 23 | 1.73 K Increased by +N/A% | -4.02 M Decreased by -377.78% | Decreased by -233.21 K% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -1.03 M Decreased by -256.01% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 950.00 Increased by +N/A% | -2.38 M Decreased by -2.39 K% | Decreased by -250.32 K% - |
| Sep 30, 22 | 0.00 Decreased by N/A% | -1.15 M Decreased by -720.46% | Decreased by N/A% - |
| Jun 30, 22 | 0.00 - | -842.00 K - | Decreased by N/A% - |
| Mar 31, 22 | 0.00 - | -290.06 K - | Decreased by N/A% - |
| Jun 30, 21 | N/A - | -95.45 K - | - - |